A Novel Subtype of the Prostacyclin Receptor Expressed in the Central Nervous System

Abstract

By use of several prostacyclin analogs and an in vitro autoradiographic technique, we have found a novel subtype of the prostacyclin receptor, one having different binding properties compared with those of the known prostacyclin receptor in the rat brain. Isocarbacyclin, which is a potent agonist for the known prostacyclin receptor, had high affinity for the novel subtype (dissociation constant (K d ) of 7.8 nM). However, iloprost, which is usually used as a stable prostacyclin analog, showed low affinity binding ( 3 H]iloprost also had high affinity in these regions, and the binding specificity was similar to that for the known prostacyclin receptor. Hemilesion studies of striatal neurons lesioned by kainate or of dopaminergic afferents lesioned by 6-hydroxydopamine revealed that the binding sites of the novel subtype exist on neuronal cells in the striatum, but not on the presynaptic terminal of afferents or on glial cells. Electrophysiological studies carried out in the CA1 region of the hippocampus revealed that prostacyclin analogs have a facilitatory effect on the excitatory transmission through the novel prostacyclin receptor. The widespread expression of the prostacyclin receptor in the central nervous system suggests that prostacyclin has important roles in neuronal activity. Prostaglandins (PGs)1 and thromboxane are formed from arachidonic acid by cyclooxygenase and the respective synthase for each PG, such as PGD synthase and PGI 2 synthase. These prostanoids exert a variety of functions through their specific membrane receptors coupled to G proteins not only in the peripheral organs, but also in the central nervous system. For example, PGD 2 acts as a sleep inducer (1, 2), produces hypothermia (3), inhibits luteinizing hormone-releasing hormone release (4), and is involved in biphasic modulation of pain sensation (5) and modification of olfaction (6). PGE 2 has hyperthermic (7), sedative (8), anticonvulsive (9, 10), and antidiuretic effects (11) and induces wakefulness (12, 13), stimulates luteinizing hormone-releasing hormone release (14), modifies pain (5, 9), and regulates food intake (11). Also, PGF 2␣ has an antidiuretic effect (15) and an inhibitory effect on oxytocin release (16). These three PGs are reported to be involved in the modulation of neurotransmitter release as well (17). Prostacyclin, discovered in 1976, is known to be a potent vasodilator and also to have an inhibitory effect on platelet aggregation (18). In the brain, however, it is not clear whether prostacyclin has specific functions or not. It seems that the chemical instability of prostacyclin and lack of knowledge about the prostacyclin receptor in the brain have hampered the investigation.Recently, we reported the presence and distribution of the prostacyclin receptor in the central nervous system by use of [ 3 H]iloprost, a stable prostacyclin analog, and an in vitro autoradiographic technique (19). High density binding was observed in the nucleus of the solitary tract (NTS) and in the spinal trigeminal nucleus in the lowe...

A Cyclooxygenase-2 Inhibitor Ameliorates Behavioral Impairments Induced by Striatal Administration of Epidermal Growth Factor

“…This elevated dopamine metabolism, but not the increase in the tyrosine hydroxylase activity, was reversed by subchronic treatment with the Cox-2 inhibitor celecoxib. Previous reports demonstrated that prostaglandins influence the activity of excitatory neurons and monoaminergic neurons (Takechi et al, 1996;Oida et al, 1997;Nakamura et al, 2001;Matsuoka et al, 2005;Sang et al, 2005). Given the defined roles of EGF and prostaglandin, we speculate that EGF may increase dopamine synthesis and prostaglandins may enhance its release.…”

Effect of TTC-909 on Cerebral Infarction Following Permanent Occlusion of the Middle Cerebral Artery in Stroke Prone Spontaneously Hypertensive Rats

“…The precise mechanisms of the neuroprotective effects of TTC-909 are not clear. A novel prostacyclin receptor showing high affinity to TEI-7165 has been detected in a variety of brain regions, such as thalamus, lateral septal nucleus, hippocampus cerebral cortex, striatum and dorsal cochlear nucleus (28). This novel subtype was shown to exist on neuronal cells.…”

Prostaglandin I 2 upregulates the expression of anterior pharynx‐defective‐1α and anterior pharynx‐defective‐1β in amyloid precursor protein/presenilin 1 transgenic mice

“…However, knowledge concerning the specific function of PGI 2 in the human brain is limited. Indeed, the assumption that PGI 2 is synthesized in brain tissue in vivo is based on observations in primary culture of astrocytes and meningeal cells (Murphy et al ., 1985) as well as of the expression of PGI 2 receptor (PI) in the rodent brain (Oida et al ., 1995; Takechi et al ., 1996). Siegle et al .…”